{'fraction_non_alphanumeric': 0.024299065420560748, 'fraction_numerical': 0.0006230529595015577, 'mean_word_length': 4.970260223048327, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Higher mortality risk in African American women with triple‐negative breast cancer

recently, adoptive T-cell immunotherapies to treat this often recurrent and fatal disease, have convinced him that primary and secondary prevention of cancer is on the horizon despite the repeated setbacks and challenges of harnessing the immune system to prevent and treat ovarian and cervical cancer. While it is now possible to generate immune cells against cancer using either vaccines or cell therapy approaches, Dr. Odunsi cautions that the cancer always fights back. His work currently concentrates on determining how to block the ability of cancer cells to resist immunotherapy. “I think the immune system holds the key to a cure for cancer in the future,” he says. Highlighting the advances made in vaccinemediated cancer, notably in HPV–associated cervical cancer, Dr. Odunsi believes this primary prevention strategy will one day be available for other types of cancer that are not caused by viruses. Dr. Odunsi’s ability to lead complex teams to discover innovative ways to address cancer at the Roswell Park Comprehensive Cancer Center was one of his distinguishing characteristics, says Richard C. Koya, MD, PhD, who worked with Dr. Odunsi for 7 years at Roswell Park. According to Dr. Koya, Dr. Odunsi was instrumental in building Roswell Park’s Center for Immunotherapy from the ground up. “This feat truly showed his amazing leadership and talent,” says Dr. Koya, who continues to work closely with Dr. Odunsi in clinical and scientific research after being recruited as a professor to UChicago Medicine.